US86889P2083 - Common Stock
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis...
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043...
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules ...
Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043- Completed enrollment...
SRZN stock results show that Surrozen missed analyst estimates for earnings per share the first quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Surrozen (NASDAQ:SRZN) just reported results for the first quarter of 2023.Surr...
SRZN stock results show that Surrozen beat analyst estimates for earnings per share the second quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Surrozen (NASDAQ:SRZN) just reported results for the second quarter of 2023.Sur...
SRZN stock results show that Surrozen missed analyst estimates for earnings per share the third quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Surrozen (NASDAQ:SRZN) just reported results for the third quarter of 2023.Surr...
Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to...
SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end...
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death of...
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end...
SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering...
Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b...
SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), today announced that it will...
We're starting off Friday with an overview of the biggest pre-market stock movers traders will want to keep an eye on today!
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted...